Cipla Ltd.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) Albendazole Tablets 200mg from the United States Food and Drug Administration (USFDA). The company’s Albendazole Tablets 200mg is AB-rated generic therapeutic equivalent version of Impax Laboratories, Inc.'s, Albenza.

It is an anthelmintic drug indicated for use in treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. According to IQVIA (IMS Health), Albenza had US sales of around $99 million for the 12-month period ending July 2018. The product is available for shipping immediately.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.